首页> 美国卫生研究院文献>Oncology Letters >Expression of miR-146a in patients with ovarian cancer and its clinical significance
【2h】

Expression of miR-146a in patients with ovarian cancer and its clinical significance

机译:miR-146a在卵巢癌患者中的表达及其临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present retrospective study was to compare microRNA (miR)-146a expression levels in primary tumors and omental metastases of 48 patients, who had undergone surgery for advanced ovarian serous cancer. Possible correlations between miR-146a expression level and clinicopathological features were investigated, including chemosensitivity and survival. miR-146a was evaluated in formalin-fixed, paraffin-embedded samples. miR-146a expression level in primary tumors was demonstrated to be increased in comparison with normal ovary tissues (P=0.02) and metastases (P=0.01). A negative correlation was demonstrated between miR-146a expression in primary tumors and serum levels of cancer antigen 125 (R=−0.37; P=0.03) and Risk of Malignancy Algorithm index (R=−0.79; P=0.0007). Overall survival positively correlated with miR-146a expression in primary tumor tissue samples (R=0.38; P=0.01). Probability of survival was decreased in patients with low miR-146a expression levels in primary tumor tissues (hazard ratio=0.21; P=0.003). Lower levels of miR-146a in primary tumor tissue samples were correlated with a shorter progression-free survival (P=0.04) and platinum-resistance of metastases (P=0.006). In conclusion, miR-146a may be a prognostic marker for serous ovarian cancer.
机译:这项回顾性研究的目的是比较48位接受晚期卵巢浆液性癌手术的患者的原发肿瘤和网膜转移中的microRNA(miR)-146a表达水平。研究了miR-146a表达水平与临床病理特征之间的可能相关性,包括化学敏感性和生存率。在福尔马林固定石蜡包埋的样品中评估了miR-146a。与正常卵巢组织(P = 0.02)和转移灶(P = 0.01)相比,miR-146a在原发性肿瘤中的表达水平得到了提高。在原发性肿瘤中的miR-146a表达与血清癌抗原125水平之间存在负相关性(R = -0.37; P = 0.03)和恶性肿瘤风险指数(R = -0.79; P = 0.0007)。总生存与原发肿瘤组织样品中miR-146a表达呈正相关(R = 0.38; P = 0.01)。在原发性肿瘤组织中miR-146a表达水平低的患者生存率降低(危险比= 0.21; P = 0.003)。原发肿瘤组织样品中较低的miR-146a水平与较短的无进展生存期(P = 0.04)和转移的铂耐药性(P = 0.006)相关。总之,miR-146a可能是浆液性卵巢癌的预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号